Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ALX Oncology Holdings Inc. filings document a clinical-stage biotechnology issuer focused on cancer therapeutics and its Nasdaq-listed common stock. Recent 8-K reports furnish quarterly and annual financial results, corporate updates, clinical data releases for evorpacept and ALX2004, preliminary cash and investment information, and capital-structure disclosures tied to common stock and pre-funded warrant financing.
Proxy and governance filings describe board matters, executive compensation, equity awards, and shareholder voting items. Other material-event reports cover officer appointments, employment and compensatory arrangements, and amendments to the 2025 Inducement Equity Incentive Plan under Nasdaq inducement award rules.
ALX Oncology Holdings CEO Jason Lettmann reported a routine tax-related share withholding. On the RSU vesting date, 2,201 shares of common stock were withheld at $2.27 per share to cover his tax liability, a non‑market disposition. Following this, he directly owns 305,920 shares, which include 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
ALX Oncology Holdings CEO Jason Lettmann reported a routine tax-related share withholding. On the RSU vesting date, 2,201 shares of common stock were withheld at $2.27 per share to cover his tax liability, a non‑market disposition. Following this, he directly owns 305,920 shares, which include 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
RA Capital Management and affiliated investors report a significant passive stake in ALX Oncology Holdings Inc. They beneficially own 13,117,106 shares of common stock, representing 9.99% of the company’s outstanding shares, calculated under a 9.99% beneficial ownership blocker.
The Fund directly holds 13,011,849 common shares and pre-funded warrants exercisable for up to 12,473,803 additional shares, but the warrants cannot be exercised if ownership would exceed 9.99%. Voting and investment power over the reported securities is delegated to RA Capital, with certain entities and individuals disclaiming beneficial ownership for purposes other than Section 13(d) reporting.
ALX Oncology Holdings Inc. (ALXO) received a Schedule 13G disclosing a significant passive ownership stake by TCG Crossover funds and Chen Yu. The filing reports that TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., through their Delaware general partners, each beneficially own 6,505,925 and 6,505,924 shares of Common Stock, respectively, representing 5.0% of the class for each fund.
Chen Yu, as sole managing member of both general partners, is reported to beneficially own 13,011,849 shares of Common Stock, or 9.9% of the outstanding shares, based on 131,197,113 shares of Common Stock. The filing explains that additional shares underlying Pre-Funded Warrants, totaling 3,050,159 for TCG Crossover II and 3,050,158 for TCG Crossover III, are excluded because a 9.99% Beneficial Ownership Limitation prevents exercise within 60 days. The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of ALX Oncology.
venBio Global Strategic Fund II L.P. purchased 3,184,713 shares of ALX Oncology common stock at $1.57 per share in a registered underwritten follow-on offering that closed on February 2, 2026, for an aggregate of approximately $5,000,000, and this amendment updates their Schedule 13D holdings.
Following the transaction, venBio-affiliated funds report beneficial ownership of 4,431,600 shares (3.4%) and 8,453,038 shares (6.4%). Robert J. Adelman reports beneficial ownership of 12,984,044 shares (9.9%), and Corey S. Goodman reports 13,163,549 shares (10%), including 111,541 shares underlying stock options exercisable within 60 days and shares held through a trust and Emaldi Corporation.
The ownership percentages are based on 54,218,001 shares outstanding as of October 31, 2025, plus 76,979,112 shares issued in the February 2026 offering and, for Mr. Goodman, 111,541 option shares. On January 20, 2026, Mr. Goodman was also awarded 40,400 stock options vesting in 12 monthly installments beginning February 20, 2026.
ALX Oncology director and 10% owner Corey S. Goodman, through entities associated with venBio, reported a large indirect purchase of the company’s common stock. On February 2, 2026, venBio Global Strategic Fund II, L.P. acquired 3,184,713 ALX Oncology shares at $1.57 per share, bringing its indirectly reported holdings to 8,453,038 shares. Additional indirect holdings reported for entities linked to Goodman include 3,969,789 shares held by venBio Global Strategic Fund, L.P., 461,811 shares held by venBio SPV, LLC, 113,287 shares held by the Goodman Barinaga Trust, and 54,083 shares held by Emaldi Corporation. Goodman serves in oversight roles at these entities and disclaims beneficial ownership of the securities, except to the extent of his indirect pecuniary interest.
ALX Oncology Holdings is offering 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares, for gross proceeds of $150,000,000.12 before fees. Net proceeds are estimated at $140.4 million, mainly to fund clinical development of evorpacept and ALX2004, plus working capital.
The company preliminarily estimates $48.3 million in cash, cash equivalents and investments as of December 31, 2025 and notes that, absent this raise, there would have been substantial doubt about its ability to continue as a going concern. Investors in this offering face immediate dilution of $0.33 per share based on a $1.57 offering price.
ALX Oncology Holdings is offering 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares, for gross proceeds of $150,000,000.12 before fees. Net proceeds are estimated at $140.4 million, mainly to fund clinical development of evorpacept and ALX2004, plus working capital.
The company preliminarily estimates $48.3 million in cash, cash equivalents and investments as of December 31, 2025 and notes that, absent this raise, there would have been substantial doubt about its ability to continue as a going concern. Investors in this offering face immediate dilution of $0.33 per share based on a $1.57 offering price.
ALX Oncology Holdings Inc. entered an underwriting agreement to sell 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares, raising approximately $150 million in gross proceeds. The common stock is priced at $1.57 per share and the pre-funded warrants at $1.569 each.
The offering is fully underwritten by Piper Sandler, UBS and Wells Fargo and is expected to close on February 2, 2026, subject to customary conditions. Each pre-funded warrant has a $0.001 exercise price, can be exercised for cash or on a cashless basis, and includes ownership caps at 4.99% or 9.99%, adjustable up to 19.99% with advance notice.
ALX Oncology Holdings Inc. entered an underwriting agreement to sell 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares, raising approximately $150 million in gross proceeds. The common stock is priced at $1.57 per share and the pre-funded warrants at $1.569 each.
The offering is fully underwritten by Piper Sandler, UBS and Wells Fargo and is expected to close on February 2, 2026, subject to customary conditions. Each pre-funded warrant has a $0.001 exercise price, can be exercised for cash or on a cashless basis, and includes ownership caps at 4.99% or 9.99%, adjustable up to 19.99% with advance notice.
ALX Oncology Holdings Inc. reported new early-stage clinical data and a preliminary year-end cash figure. The company highlighted topline findings from a Phase 1b/2 trial of its investigational CD47 inhibitor evorpacept combined with Jazz Pharmaceuticals’ ZIIHERA (zanidatamab-hrii) in heavily pretreated metastatic breast cancer patients.
In an exploratory analysis of HER2-positive metastatic breast cancer, CD47 expression appeared predictive of evorpacept activity. Separately, ALX Oncology estimated it held approximately $48.3 million in cash, cash equivalents, and short- and long-term investments as of December 31, 2025, noting this figure is unaudited, preliminary, and subject to change after completion of year-end closing procedures.
ALX Oncology Holdings Inc. reported new early-stage clinical data and a preliminary year-end cash figure. The company highlighted topline findings from a Phase 1b/2 trial of its investigational CD47 inhibitor evorpacept combined with Jazz Pharmaceuticals’ ZIIHERA (zanidatamab-hrii) in heavily pretreated metastatic breast cancer patients.
In an exploratory analysis of HER2-positive metastatic breast cancer, CD47 expression appeared predictive of evorpacept activity. Separately, ALX Oncology estimated it held approximately $48.3 million in cash, cash equivalents, and short- and long-term investments as of December 31, 2025, noting this figure is unaudited, preliminary, and subject to change after completion of year-end closing procedures.
ALX Oncology Holdings Inc. reported that its Chief Financial Officer, Shantharam Harish, received a grant of stock options on January 26, 2026. The award covers 303,000 stock options with an exercise price of $1.48 per share, giving the right to buy common stock.
The options vest in 48 equal monthly installments starting on February 26, 2026, and are scheduled to expire on January 25, 2036. Following this grant, Harish beneficially owns 303,000 derivative securities directly in the form of these stock options.
ALX Oncology Holdings Inc. officer Shelly Pinto was granted 192,000 stock options on January 26, 2026. These options have an exercise price of $1.48 per share and were awarded at a cost of $0.00 to Pinto.
The options relate to ALX Oncology common stock and are held directly. They become exercisable over time, vesting in 48 equal monthly installments beginning on February 26, 2026, and are scheduled to expire on January 25, 2036 if not exercised.